Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

RET-IRD-04

In this page

Clinical Trial

RET-IRD-04 Unknown
RET-IRD-04

Efficacy and safety of QLT091001 in subjects with Inherited Retinal Disease (IRD) caused by gene mutations.

Phase 3
Interventional

Disease

Disease type

Leber Congenital Amaurosis

Orphan drug recognition

No

Inclusion / Exclusion

Opening date

12/12/2017

Closing date

12/12/2018

Funding

industry

Members involved

Main investigators

Pr Michael LARSEN

Representative

Denmark

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Others investigators

Line Kessel

Denmark

Genetic Diagnostics (TWG6), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

ERN EYE member investigating site

HCP : Principal investigators